Allergan acquires Life Cell business from Acelity and with it Alloderm Regenerative Tissue Matrix and Strattice Reconstructive Tissue.

Acelity L.P.announced a definitive agreement with Allergan for the acquisition of Acelity�s LifeCell business unit for $2.9 billion in cash. Upon completion of the transaction, LifeCell�s industry-leading regenerative medicine and reconstructive surgery portfolio will be combined with Allergan�s leading portfolio of medical aesthetics and breast implants and tissue expanders, enhancing the potential for continued long-term growth of the LifeCell portfolio. The combination will offer Allergan access to a strong commercial channel, robust R&D pipeline and demonstrated manufacturing capability. LifeCell is recognized for applications in plastic and reconstructive surgeries and abdominal wall procedures. The LifeCell portfolio encompasses regenerative and reconstructive acellular tissue matrices for repair of soft tissue defects, as well as autologous fat grafting solutions. Leading products include Alloderm Regenerative Tissue Matrix, a human allograft tissue matrix which allows for a strong, intact repair in breast reconstruction post-mastectomy procedures and other surgical applications, by providing soft tissue reinforcement; and Strattice Reconstructive Tissue, a porcine based tissue matrix for reinforcement of soft tissue in challenging hernia repair procedures.